Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy
- PMID: 21199965
- PMCID: PMC3076045
- DOI: 10.1001/archgenpsychiatry.2010.184
Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy
Abstract
Context: Cognitive impairment in late-life depression is a core feature of the illness.
Objective: To test whether donepezil hydrochloride and antidepressant therapy is superior to placebo and antidepressant therapy in improving cognitive performance and instrumental activities of daily living and in reducing recurrences of depression over 2 years of maintenance treatment.
Design: Randomized, double-blind, placebo-controlled maintenance trial.
Setting: University clinic.
Participants: One hundred thirty older adults aged 65 years and older with recently remitted major depression.
Interventions: Random assignment to maintenance antidepressant pharmacotherapy and donepezil or to maintenance antidepressant pharmacotherapy and placebo.
Main outcome measures: Global neuropsychological performance, cognitive instrumental activities of daily living, and recurrent depression.
Results: Donepezil and antidepressant therapy temporarily improved global cognition (treatment × time interaction, F₂,₂₁₆ = 3.78; P = .03), but effect sizes were small (Cohen d = 0.27, group difference at 1 year). A marginal benefit to cognitive instrumental activities of daily living was also observed (treatment × time interaction, F₂,₁₃₇ = 2.94; P = .06). The donepezil group was more likely than the placebo group to experience recurrent major depression (35% [95% confidence interval {CI}, 24%-46%] vs 19% [95% CI, 9%-29%], respectively; log-rank χ² = 3.97; P = .05; hazard ratio = 2.09 [95% CI, 1.00-4.41]). Post hoc subgroup analyses showed that of 57 participants with mild cognitive impairment, 3 of 30 participants (10% [95% CI, 0%-21%]) receiving donepezil and 9 of 27 participants (33% [95% CI, 16%-51%]) receiving placebo had a conversion to dementia over 2 years (Fisher exact test, P = .05). The mild cognitive impairment subgroup had recurrence rates of major depression of 44% with donepezil vs 12% with placebo (likelihood ratio = 4.91; P = .03). The subgroup with normal cognition (n = 73) showed no benefit with donepezil and no increase in recurrence of major depression.
Conclusions: Whether a cholinesterase inhibitor should be used as augmentation in the maintenance treatment of late-life depression depends on a careful weighing of risks and benefits in those with mild cognitive impairment. In cognitively intact patients, donepezil appears to have no clear benefit for preventing progression to mild cognitive impairment or dementia or for preventing recurrence of depression.
Trial registration: clinicaltrials.gov Identifier: NCT00177671.
Figures



References
-
- Nebes RD, Pollock BG, Houck PR, et al. Persistence of cognitive impairment in geriatric patients following antidepressant treatment: A randomized, double-blind clinical trial with nortriptyline and paroxetine. J Psychiatr Res. 2003;37:99–108. - PubMed
-
- Butters MA, Becker JT, Nebes RD, et al. Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry. 2000;157(12):1949–54. - PubMed
-
- Bhalla RK, Butters MA, Mulsant BH, et al. Persistence of neuropsychologic deficits in the remitted state of late-life depression. Am J Geriatr Psychiatry. 2006;14(5):419–27. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- UL1 TR000005/TR/NCATS NIH HHS/United States
- R01 MH083660/MH/NIMH NIH HHS/United States
- R01 AG022462/AG/NIA NIH HHS/United States
- R01 MH043823/MH/NIMH NIH HHS/United States
- P30 MH071944/MH/NIMH NIH HHS/United States
- P50 AG005133/AG/NIA NIH HHS/United States
- K01 EB009724/EB/NIBIB NIH HHS/United States
- P50 AG05133/AG/NIA NIH HHS/United States
- R01 AG030653/AG/NIA NIH HHS/United States
- R01 MH037869/MH/NIMH NIH HHS/United States
- R49 CE001495/CE/NCIPC CDC HHS/United States
- R21 AG033387/AG/NIA NIH HHS/United States
- R01 MH043832/MH/NIMH NIH HHS/United States
- R01MH072947/MH/NIMH NIH HHS/United States
- AG030653/AG/NIA NIH HHS/United States
- R01 MH072947/MH/NIMH NIH HHS/United States
- KL2 TR000146/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous